Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Trastuzumab

    Tag: trastuzumab

    You Searched For "Trastuzumab"
    Biocon gets EIR from USFDA for Bengaluru biologics unit

    Biocon gets EIR from USFDA for Bengaluru biologics unit

    Medical Dialogues Bureau6 Nov 2019 9:19 AM IST
    New Delhi: Biopharmaceutical firm Biocon on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for its...
    Biocon, Mylan gets Canadian nod for biosimilar of cancer drug Herceptin

    Biocon, Mylan gets Canadian nod for biosimilar of cancer drug Herceptin

    Farhat Nasim23 May 2019 11:59 AM IST
    Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the...
    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    Medical Dialogues Bureau10 May 2019 9:00 AM IST
    The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Meghna A Singhania11 April 2019 10:50 AM IST
    Mumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
    AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal

    AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal

    Garima29 March 2019 9:15 AM IST
    Under the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development...
    USFDA approves Mylan, Biocon

    USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta

    Ruby Khatun Khatun6 Jun 2018 10:30 AM IST
    HERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
    Roche plea in HC on cancer drug not maintainable: Biocon, Mylan

    Roche plea in HC on cancer drug not maintainable: Biocon, Mylan

    Ruby Khatun Khatun12 Jan 2018 10:27 AM IST
    New Delhi: Generic drug makers Biocon and Mylan told the Delhi High Court that Swiss pharma major Roche's civil suit, challenging DCGI approvals...
    EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars

    EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars

    Ruby Khatun Khatun2 Dec 2017 10:00 AM IST
    HERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
    Roche sues Pfizer to bar biosimilar of cancer drug Herceptin

    Roche sues Pfizer to bar biosimilar of cancer drug Herceptin

    Ruby Khatun Khatun22 Nov 2017 10:00 AM IST
    Roche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block...
    Mylan seeks EMA approval for 2 biosimilars

    Mylan seeks EMA approval for 2 biosimilars

    Ruby Khatun Khatun9 Nov 2017 10:32 AM IST
    New Delhi: Biocon said that its partner Mylan has re-submitted marketing authorization applications with the European Medicines Agency for two...
    NPPA Slashes price of another 54 Critical medcines. Check out the details

    NPPA Slashes price of another 54 Critical medcines. Check out the details

    Geeta Sharma Sharma14 May 2016 4:05 PM IST
    The common man ailing from critical diseases has received a reliever through the recent National Pharmaceutical Pricing Authority (NPPA) directive to...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok